Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Bibliographic record
Abstract
8040 Background: The immunostimulatory monoclonal antibody elotuzumab exhibits a dual mechanism of action, directly activating natural killer cells and mediating myeloma cell death via antibody-dependent cell-mediated cytotoxicity. In ELOQUENT-2 (NCT01239797), ELd showed sustained reduction in risk of disease progression or death at 2- (30%), 3- (27%), and 4-y (29%) FU vs Ld, and a favorable trend in overall survival (final analysis at 427 deaths). Here we present progression-free survival (PFS) data at 5 y, a milestone timepoint in cancer survival analyses. Methods: RRMM patients (pts) randomized 1:1 to ELd or Ld in 28-d cycles until disease progression/unacceptable toxicity. Coprimary endpoints: PFS and overall response rate (ORR) per independent review committee. Results: In all, 646 pts were randomized to ELd (n = 321) and Ld (n = 325). At database lock (Nov 29, 2017), 13% (ELd) vs 7% (Ld) of pts remained on treatment; discontinuation was mostly due to disease progression (55 vs 56%). At 5-y FU (minimum 60 mo), ELd showed 27% reduction in risk of progression or death vs Ld (HR 0.73, 95% CI 0.60–0.87) and relative improvement of 50% in PFS rate at 5 y (18 vs 12%). Pts with ≥very good partial response (ELd 36% vs Ld 30%) had the greatest reduction in risk of progression/death (HR 0.63, 95% CI 0.44–0.89). ORR was 79% (ELd) vs 66% (Ld). G3–4 AEs included blood and lymphatic system disorders (ELd vs Ld: 46 vs 46%), infections (35 vs 27%), vascular diseases (11 vs 8%), second primary malignancies (SPMs; 10 vs 6%), and cardiac disorders (5 vs 8%). Higher rate of any-grade infection (84 vs 75%) and SPMs (17 vs 11%) may reflect longer median duration of treatment with each agent of the ELd vs Ld regimens (E/L/d vs L/d: 17/17/17 vs 12/12 mo). Fewer deaths occurred with ELd than Ld (193 vs 208), mostly due to disease progression. Conclusions: Elotuzumab (+ Ld) has the longest median FU of an immuno-oncology agent in MM. At the milestone timepoint of 5 y, ELd showed sustained, durable clinically relevant improvement in PFS, a 27% reduction in the risk of progression or death, and a safety profile with minimal incremental AEs with ELd vs Ld. Study funding: BMS. Writing support: L Yee, Caudex, funded by BMS. Clinical trial information: NCT01239797.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".